Version 2 2024-11-21, 01:04Version 2 2024-11-21, 01:04
Version 1 2023-05-21, 02:14Version 1 2023-05-21, 02:14
journal contribution
posted on 2024-11-21, 01:04authored byL Hensen, PT Illing, E Bridie Clemens, THO Nguyen, M Koutsakos, CE van de Sandt, NA Mifsud, AT Nguyen, C Szeto, BY Chua, H Halim, S Rizzetto, F Luciani, L Loh, EJ Grant, PM Saunders, AG Brooks, S Rockman, TC Kotsimbos, AC Cheng, M Richards, GP Westall, LM Wakim, T Loudovaris, SI Mannering, M Elliott, SG Tangye, DC Jackson, Katie FlanaganKatie Flanagan, J Rossjohn, S Gras, J Davies, A Miller, SYC Tong, AW Purcell, K Kedzierska
Indigenous people worldwide are at high risk of developing severe influenza disease. HLA-A*24:02 allele, highly prevalent in Indigenous populations, is associated with influenza-induced mortality, although the basis for this association is unclear. Here, we define CD8<sup>+</sup> T-cell immune landscapes against influenza A (IAV) and B (IBV) viruses in HLA-A*24:02-expressing Indigenous and non-Indigenous individuals, human tissues, influenza-infected patients and HLA-A*24:02-transgenic mice. We identify immunodominant protective CD8<sup>+ </sup>T-cell epitopes, one towards IAV and six towards IBV, with A24/PB2<sub>550-558</sub>-specific CD8<sup>+</sup> T cells being cross-reactive between IAV and IBV. Memory CD8<sup>+</sup> T cells towards these specificities are present in blood (CD27<sup>+</sup>CD45RA- phenotype) and tissues (CD103<sup>+</sup>CD69+ phenotype) of healthy individuals, and effector CD27-CD45RA-PD-1<sup>+</sup>CD38<sup>+</sup>CD8<sup>+</sup> T cells in IAV/IBV patients. Our data show influenza-specific CD8<sup>+</sup> T-cell responses in Indigenous Australians, and advocate for T-cell-mediated vaccines that target and boost the breadth of IAV/IBV-specific CD8<sup>+</sup> T cells to protect high-risk HLA-A*24:02-expressing Indigenous and non-Indigenous populations from severe influenza disease.